cyrilzakka/clinical-trials huggingface dataset:
Comparing Perceptual Motor Training and Repetitive Facilitation Exercises on UE in Stroke

The aim of the study is to determine the comparative effects of perceptual motor training and repetitive facilitation exercises on upper limb quality of movement and motor function in Stroke patients.

Perceptual-motor training enhances proprioception, spatial awareness, and coordination through object manipulation. On the other hand, Repetitive facilitation exercises aim to improve motor control and reduce spasticity by stimulating muscles repetitively. Decreased dexterity, coordination, muscle tone abnormalities, and diminished sensation are frequently observed in stroke patients. Effective rehabilitation in daily tasks depends on coordinated efforts among muscles, joints, and body segments, influenced by environmental factors and personal constraints. Visual input, perception, and cognitive processing play crucial roles in action planning during rehabilitation.

This is a randomized clinical trial. The data will be collected from DHQ hospital, Sargodha. 50 stroke patients will be included using convenience sampling. The participants who meet the inclusion criteria will be randomly allocated into two groups. Twenty-five participants will be included in both Groups A and B. Group A (perceptual motor training with routine physical therapy) and Group B (Repetitive facilitation exercises with routine physical therapy) will receive 60 minutes treatment session that consists of 40 minutes of intervention and 20 minutes of routine physical therapy four sessions per week for 8 weeks.

Quality of movement will be assessed using Motor Evaluation Scale for Upper Extremity in Stroke Patients (MESUPES) and motor function by Fugl-Meyer Assessment (FMA-UE) Assessments will occur at baseline, 4 weeks, and 8 weeks. Data analysis will utilize SPSS version 27 for Windows, with statistical significance set at p ≤ 0.05.

Eligibility Criteria:
Inclusion Criteria;

* Both male and female patients.
* Age 40-65 years
* 1st ever stroke confirmed by MRI
* mild-to-moderate upper-limb motor paralysis
* sub-acute and chronic stroke patients
* ability to understand tasks such as evaluations in the intervention
* Modified Ashworth scale score \< 3
* Mini Mental State Examination Score should be\>24 out of 30

Exclusion Criteria:

* Participants who have a history of significant neurological or psychiatric disorders, other than stroke, that could interfere with upper limb motor recovery
* Patients with pain, contracture and profound atrophy in arm and fingers.
* Participants with severe cognitive dysfunction that would interfere with understanding instructions from the physician or therapist.
* Presence of any other musculoskeletal condition. e.g. (Frozen shoulder, any recent fractures of upper limb.
* Any accompanying diseases or disorders, other than stroke, that could interfere with upper extremity training.
* Uncontrolled health conditions for which exercise was contraindicated.
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

The purpose of this study is to investigate the pharmacodynamic effect of omeprazole n a Japanese non-erosive reflux disease population


Eligibility Criteria:
Inclusion Criteria:

* Patients who identified their predominant symptom as heartburn and were classifiend as Grande M or N according to Hoshihara's modofied version of Los Angeles Classification at esophagogastroduodenoscopy. Written informed consent, ability to comply with study instructions

Exclusion Criteria:

* Patients with any ongoing gastrointestinal bleeding at the time of esopgahogastroduodenoscopy, patients with any history of erosive esophagitis or any other major diseases or concommittant drugs likely to interfere with the evaluation of this study
Assessment of the Effectiveness of TA Versus LEEP for Cervical Cancer Risk Reduction in WLHIV in Mozambique

Given that WLWH are more likely to develop persistent HPV infection and CC, effective screening and the management and treatment of pre-cancerous cervical abnormalities is critical to decrease the global burden of cervical cancer. The vast majority of WLWH live in SSA, where resources are more constrained. Therefore, simple, affordable, and effective tools are needed for the prevention of cervical cancer in SSA. In this setting, the best method for treatment of screen-positive WLWH has not been determined. The proposed study will compare the effectiveness of TA vs. LEEP, for treating precursor lesions (CIN 2/3) and HPV infection in WLWH, identify the determinants of treatment failure, and develop a strategy to predict patients in whom treatment is likely to fail so that alternative treatments can be provided. Moreover, local evidence of the optimal method of treatments is necessary to inform health policy and promote adherence.

A. General purpose:

The goal of this study is to compare TA, an ablative cervical treatment modality, and LEEP, an excisional cervical treatment modality, in screen-positive WLWH patients, for eradication of hrHPV and effectiveness of treating biopsy-confirmed CIN 2/3.

B. Specific purposes

Primary Objectives:

1. Compare the effectiveness of treating biopsy-confirmed CIN 2/3 by TA versus LEEP
2. Compare the effectiveness of treating hrHPV infection by TA versus LEEP
3. Assess pain and side effects/adverse events due to TA versus LEEP

Secondary Objectives:

1. Identify the determinants of treatment failures
2. Develop a deep learning-based automated visual evaluation tool that predicts treatment failure

Eligibility Criteria:
Inclusion Criteria:

* ages 25-49 years;
* confirmed HIV infection;
* physically and mentally willing and able to participate in the study, and provide informed consent.

Exclusion Criteria:

* currently pregnant or \<6 weeks post-partum;
* had a hysterectomy and no longer have a cervix;
* a history of cervical cancer or treatment for cervical abnormalities; and
* any medical, psychiatric, or other condition that would interfere with protocol adherence, assessment of safety, and/or ability/competence to provide informed consent.
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy in combination with rituximab in CD20 positive standard risk patients. Thereafter patients receive additional consolidation and reinduction cycles combined with rituximab. In parallel minimal residual disease is evaluated. After six months and one year the decision on intensification or discontinuation of therapy is made based on results of MRD evaluation


Eligibility Criteria:
Inclusion Criteria:

* B-precursor ALL (common / pre B-ALL)
* Standard risk
* CD20 expression \>20%
* Ph/BCR-ABL negative
* Age 15-65 years (55-65 if biologically younger)
* Written informed consent

Exclusion Criteria:

* Severe complications due to leukemia or secondary illnesses
* Late relapse of childhood ALL
* Cytostatic pretreatment
* Pregnancy
* Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent
* Known severe allergy to foreign proteins
Supporting Baby Behavior Through Pediatric Offices

The primary objective of this project is to evaluate the impact on infant growth and infant-feeding practices of a low-cost series of video trainings and tools targeted to medical staff and designed to support ongoing Baby Behavior education of WIC participants.

The primary objective of this project is to evaluate the impact on infant growth and infant-feeding practices of a low-cost series of video trainings and tools targeted to medical staff and designed to support ongoing Baby Behavior education of WIC participants. The intervention, currently used in all California WIC agencies, teaches caregivers to recognize and understand healthy infant behaviors such as the range of infant cues and common patterns for sleep and crying. This project will also evaluate the acceptance, knowledge transfer, and use of the tools by health care providers and medical staff. It is expected that trained staff will be prepared to share Baby Behavior messages with their patients and that the information will be delivered quickly and easily during well-baby visits.

Eligibility Criteria:
Inclusion Criteria:

* Will attend a participating pediatric clinic for her well-baby visits
* Primiparous, singleton pregnancy
* Currently enrolled in WIC
* At least 18 years of age
* Speaks and reads English or Spanish
* Has a telephone and access to the internet
* Plans to stay in the area for 6 months after birth of infant
* Abstained from smoking during pregnancy

Exclusion criteria:

* Gave birth before 37 weeks gestation
* She and/or her infant has health condition(s) or known health risks that contraindicate breastfeeding
* She and/or her infant has health condition(s) or known health risks that impact infant growth and development
POCT Detection for Blood Concentration of Tirofiban in Acute Myocardial Infarction Based on Azo-POP Probe.

The goal of this observational study is to monitor blood drug concentration during the use of tirofiban, predict the occurrence of intraoperative and postoperative complications related to interventional therapy, and evaluate the efficacy of multiple antiplatelet drugs.The main question it aims to answer is:

1. If the POCT detection technology for blood concentration of tirofiban based on portable mass spectrometer can be used for on-site sampling, clinical testing, and immediate analysis next to patients undergoing coronary intervention therapy.
2. LC-MS/MS untargeted metabolomics analysis techniques combined with machine learning algorithms will be used to screen biomarkers for myocardial infarction.


Eligibility Criteria:
Inclusion Criteria:

* The patient meets the diagnostic criteria for STEMI (refer to the "Diagnosis and Treatment Guidelines for Acute ST Segment Elevation Myocardial Infarction (2019)")
* The onset time is less than 12 hours
* Agree to perform direct PCI
* Heart function (Killip class) ≤ Level III
* There are no direct PCI contraindications.

Exclusion Criteria:

* Patients allergic to tirofiban or/and aspirin
* Patients with a history of intracranial hemorrhage
* Patients with stroke/transient ischemic attack within six months
* Patients who have taken oral anticoagulants within 30 days before admission and cannot stop taking them
* Patients receiving clopidogrel or ticagrelor from other manufacturers or formulations due to directive events
* Patients who have received or plan to undergo fibrinolysis therapy within 24 hours
* Patients with a history of major surgery within 30 days, or those who plan to undergo major surgery during the study process
* Patients with a history of gastrointestinal bleeding within 6 months, or those with severe bleeding disorders or tendencies towards bleeding
* Patients with severe combined liver and kidney dysfunction
* Refuse to participate in this experiment.
Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and ifosfamide in treating patients who have metastatic kidney cancer.

OBJECTIVES: I. Determine the efficacy in terms of objective response after treatment with ifosfamide and doxorubicin in patients with metastatic sarcomatoid renal cell cancer. II. Determine the toxicity of this regimen in these patients. III. Determine the effect of this regimen on the survival of these patients.

OUTLINE: This is a multicenter study. Patients receive doxorubicin IV on day 1 and ifosfamide IV over 2 hours on days 1 and 2. Treatment is repeated every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 3 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven metastatic, sarcomatoid renal cell carcinoma Measurable disease At least 15 mm for pulmonary sites At least 20 mm for other sites No uncontrolled CNS metastases

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: Greater than 3 months Hematopoietic: Neutrophil count greater than 1500/mm3 Platelet count greater than 100,000/mm3 Hemoglobin greater than 9 g/dL Hepatic: Bilirubin less than 1.5 times normal Transaminases less than 2 times normal (less than 4 times normal if due to liver metastases) Renal: Creatinine less than 1.6 mg/dL Creatinine clearance greater than 60 mL/min Other: No contraindication to anthracycline treatment No unstable major organ defect No prior malignancy except basal cell skin cancer or carcinoma in situ of the uterus Not pregnant or nursing Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.


Eligibility Criteria:
Inclusion Criteria:

* Critically ill male or female subjects 18 years or older who have a baseline gastric aspirate pH less then or equal to 4
* Subjects admitted to an ICU requiring mechanically ventilated
* Subjects will have at least one additional stress ulcer risk factor

Exclusion Criteria:

* Anticipated use of pre-pyloric enteral feeding after screening until the end of study
* Physician estimated survival of less then 96 hours
* Anticipation of major surgery within 96 hours of study enrollment
A Study of Why People With Early Memory Problems Fall or Almost Fall

The purpose of this study is to identify the factors that are associated with falls and near falls in community-dwelling older adults with early-stage dementia.

The specific objectives of this six month study are to: characterize falls and near-falls in community dwelling older adults with early-stage dementia; determine which potentially modifiable physical fall risk factors contribute to falls and near-falls in older adults with early-stage dementia; examine the relationship between dementia sub-type, medical and neuropsychological factors, balance and gait, and falls and near-falls in community dwelling older adults with early-stage dementia.

Eligibility Criteria:
Inclusion Criteria:

* males or females over the age of 50 with early-stage dementia as described by Global Deterioration Scale levels 2,3,4 or 5.

Exclusion Criteria:

* subjects who have a medical condition that significantly predispose them to falls (Meneire's disease or Parkinson's disease)
* subjects without a caregiver/spouse to assist with the completion of a Fall Diary
* subjects unable to stand independently or safely walk a short distance either unaided or with the support of an assistive device
* subjects unable to safely complete the balance and gait evaluations.
Testing the Effects of Telehealth Monitoring on Rehospitalization and Self Care for Heart Failure Patients in Home Care

We are testing the use of telehealth technology that includes self monitoring of blood pressure, weight, blood sugar, and oxygen levels for patients with heart failure who are receiving home care. We are interested to learn if using the equipment results in improved self care and decreased incidence of rehospitalization.

Despite telehomecare's potential to enhance patients' self-care in a cost-effective manner, few studies have evaluated its efficacy. Reported studies were conducted prior to the introduction of Medicare's prospective payment system for home care and evaluated the use of telehomecare in addition to traditional home visits. None examined patients' involvement in decision-making regarding the use of such technology in meeting their health care needs. Available data suggest that telehomecare may improve self-care and enhance outcomes for elders with heart failure but major gaps in knowledge exist regarding the clinical and cost effectiveness of this technology when decisions regarding its use are negotiated with patients and when it substitutes for traditional nurse visits under the recently introduced changes in the financing of home health care.

Patient and cost outcomes will include: self-care, health care resource utilization, health status, quality of life, satisfaction, access to care and cost effectiveness. Data analysis will consist of a variety of statistical tests, and estimates of treatment costs. Findings will help guide optimal use of telehomecare in promoting self-care in the growing population of chronically ill elders whose conditions are characterized by high morbidity, complex therapies and poor quality and cost outcomes.

Subjects will be enrolled from the acute care setting and will be randomized to receive home care with or without telehealth monitoring. Baseline and follow-up interviews will be conducted at admission, 60, 120 and 180 days.

Eligibility Criteria:
Inclusion Criteria:

* Primary diagnosis of heart failure, English speaking; mentally competent, weigh less than 450 pounds, have a telephone in their home; have Medicare insurance; are able to see, hear, place a cuff on their arm, and stand on a scale to weigh themselves, receiving home care from Penn Care at Home.

Exclusion Criteria:

* cognitive impairment, weight \> 450 pounds, receiving disease management or on a heart transplant waiting list, receiving home care from a non- participating agency.
The Effect of the Operating Room Environment on Patients Experienced With Virtual Reality Glasses Before Surgery

This study was planned as a randomized controlled experimental study with a pretest-posttest design to examine the effect of the operating room environment experience of preoperative patients using virtual reality glasses on the patients' preoperative surgical fear level and care perceptions.

Today, virtual reality is used in many areas such as medical diagnosis and treatment by reflecting three-dimensional images animated on the computer as if it were a real experience. Procedural pain, facilitating interventional procedures with a game-based video demonstration in children, and outpatient surgeries such as circumcision surgery can be used to provide patients with this "real world" experience, its use has also become widespread in areas such as wound care and in nursing education due to the increase in malpractice cases . In line with patient experiences, the benefits of virtual reality technology have been documented in the literature and its use in nursing care is increasing . Informing the patient to improve the quality of care, managing pain during painful interventional procedures, and reducing surgery-related fear reduces wound healing and hospital stay, especially in surgical patients . In the literature, patients' pre-operative problems such as lack of knowledge about the surgery, operating room environment, surgical procedures, etc. It is reported that they experience anxiety and fear related to many factors. It also emphasizes the importance of informing the patient before surgery within the scope of Enhance Recovery After Surgery (ERAS) procedures (Joshi \& Kehlet, 2019). In line with ERAS protocols, preoperative education and information have been proven to provide positive postoperative recovery. Informing the patient about the operating room environment is the most important element in accelerating surgical recovery. The operating room environment can be seen as a stress factor for patients. Therefore, in this study, we aimed to examine the effect of informing patients about the operating room environment, supported by visuals, on the patient's fear and perceptions of care. In addition, it is thought that this information and experience will affect the patient's vital signs and that the patient's need for premedication will also change. It is thought that the results of this study will positively affect patient outcomes by improving the quality of patient care.

Eligibility Criteria:
Inclusion Criteria:

* Being 18 years or older
* Agreeing to participate in the research
* Having elective cholecystectomy surgery
* Knowledge of Turkish and no communication barriers
* Having surgery for the first time and not having seen the operating room environment

Exclusion Criteria:

* Being 18 years of age or younger
* Refusal to participate in the research
* Having undergone surgery and having seen the operating room environment before Not knowing Turkish and having any communication barrier
Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

This is a multi-center, open-label, single-arm, phase 4 study to evaluate the efficacy of perampanel added to monotherapy for partial onset seizures with or without secondarily generalized seizures (total seizures).

This multi-center, open-label, single-arm study evaluating the efficacy of perampanel added to monotherapy for partial onset seizures consists of 2 periods: Titration Period (12 weeks) and Maintenance Period (24 weeks). During the Titration Period, participants will begin receiving perampanel 2 milligrams per day (mg/day) and be up-titrated in no less than 2-week intervals in increments of 2 mg up to 12 mg according to the investigator's judgment. Upon entering the Maintenance Period, participants will receive the last dose they achieved at the end of the Titration Period and will continue receiving this dose once daily for the remainder of the study.

Eligibility Criteria:
Inclusion Criteria:

* Have a diagnosis of epilepsy with partial onset seizures with or without secondarily generalized seizures according to the International League Against Epilepsy's Classification of Epileptic Seizures (1981)
* Need an initial add-on therapy after failure to control seizures with the first or further monotherapy at the optimal dose and duration
* Despite antiepileptic drug (AED) treatment within the last 8 weeks, participants must have had greater than or equal to 2 partial onset seizures, and the interval between those seizures should be more than 24 hours prior to Visit 1 (Week 0).
* Are currently being treated with stable doses of monotherapy for 8 weeks prior to Visit 1 (Week 0) (Standard AEDs)
* If antidepressants or antianxiety drugs are used, participants must be receiving stable doses and administrations of antidepressants or antianxiety drugs for 8 weeks prior to Visit 1 (Week 0)

Exclusion Criteria:

* Females who are pregnant (positive beta-human chorionic gonadotropin (β-hCG test) or breastfeeding
* Presence of previous history of Lennox-Gastaut syndrome
* Presence of nonmotor simple partial seizures only
* Presence of primary generalized epilepsies or seizures such as absences and/or myoclonic epilepsies
* A history of status epilepticus within 12 weeks before Visit 1 (Week 0)
* Participants on antipsychotics or who have psychotic disorder(s) or unstable recurrent affective disorder(s) with a history of attempted suicide within 1 year before Visit 1 (Week 0)
* Presence of a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors
* Concomitant use of barbiturates (except for seizure control indication and premedication for electroencephalogram \[EEG\]) and benzodiazepines (except for seizure control indication) within 8 weeks prior to Visit 1 (Week 0)
* Use of intermittent rescue benzodiazepines (that is, 1 to 2 doses over a 24-hr period considered one-time rescue) 2 or more times in an 8-week period prior to Visit 1 (Week 0)
* Participant who is participating in other intervention clinical trial